November 18, 2021
Xcenda is a proud supporter of Virtual ISPOR EU 2021
For more than 25 years, manufacturers have turned to Xcenda’s leading team of value experts, transforming evidence, policy insights, and market intelligence into effective global market access strategies. Founded in the application of health outcomes and reimbursement, Xcenda, a part of AmerisourceBergen, is a comprehensive global commercialization partner helping clients effectively navigate today’s complex healthcare landscape. Our bench of diverse experts shares a passion to help you deliver the most distinctive body of evidence that demonstrates your value story.
Trust in our committed team of over 700 global associates so you can focus on what matters most—helping patients gain access to your brand.
Meeting global needs for our customers
Our Xcenda Germany team comprises of 60+ highly qualified economists, natural scientists, pharmacists, and methodically skilled data analysts who specialize in scientific, contract research, and conducts healthcare-related studies in Germany and Europe. Our team in Germany has expertise in benefit analysis of pharmaceuticals, AMNOG dossiers, pricing, and reimbursement, analysis of primary and secondary research data, health services research, health economic evaluation, as well as scientific communication (publications, workshops, and presentations).
Xcenda also has global team members located in key markets such as the United Kingdom, Switzerland, and Spain, providing our manufacturer customers with global reach and expertise to meet local market access needs.
Xcenda continues excellence in innovative research
We are proud to present the following research at ISPOR EU 2021 Virtual.
|Cost-Effectiveness of Granulocyte Colony Stimulating Factors (G-CSFS) for the Prevention of Febrile Neutropenia in Breast Cancer Patients||Koptelova N, Mehl A, Chaplin S, Maiese B|
|Economic burden of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency in Europe, from the caregivers’ perspective (PTC Therapeutics Switzerland GmbH, Zug, Switzerland)||Solanke O, Martel MJ, Buesch K|
|Economic burden of informal care and productivity loss due to caring for individuals with aromatic l-amino acid decarboxylase (AADC) deficiency - an analysis for the US (PTC Therapeutics Switzerland GmbH, Zug, Switzerland)||Buesch K, Solanke O, Williams K, Skrobanski H, Zhang R, Acaster S, Martel MJ|
|Health Economic Impact of Phenylketonuria - a Retrospective Claims Database Study in France||Okhuoya P, Altevers J, Arnoux JB, Bouée S, Charrière S, Jacob C, Jha A, Maillot F, Schneider KM|
|Economic Burden of Secondary Hyperparathyroidism in Germany: A Matched Comparison Using Administrative Claims Data||Meise D, Schneider KM, Stremel T, Kaiser EA, Soro M|
|Healthcare Utilization and Costs of Human Papillomavirus (HPV) Associated Anogenital Diseases in Young Women - an Analysis of Statutory||Reuschenbach M, Mihm S, Wölle R, Wähner C, Schneider KM, Jacob C, Greiner W, Hampl M, Goodman E|
Meet with Xcenda